Tag Archive for: mydecine
https://psychedelicspotlight.com/wp-content/uploads/2022/08/200.png 802 1200 James Hallifax https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png James Hallifax2022-08-19 18:21:402022-08-24 16:29:21Psychedelic Stocks: MindMed and atai Slash their Pipelines, Mydecine Collapses
Psychedelic Stocks: MindMed and atai Slash their Pipelines, Mydecine CollapsesBusiness, Stock Reports
The psychedelic renaissance hits a rough patch as major companies look to tighten their belts or face total collapse. What’s happening with Psychedelic Stocks?
https://psychedelicspotlight.com/wp-content/uploads/2022/07/Company_Press_Releases_TemplateArtboard-1-2.jpg 875 1310 James Hallifax https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png James Hallifax2022-07-22 17:33:112022-07-22 17:33:11A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 Trial
A Big Week for Psychedelic Stocks: 2 CEOs Step Down, MDMA Patents and a Phase 3 TrialBusiness, Stock Reports
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research
https://psychedelicspotlight.com/wp-content/uploads/2021/12/Psychedelic_Business_Spotlight_Mydecine_Tryp_Therapeutics_MindMed_Sage_Institute_Ixtlan_Bioscience_Psychedelic_Spotlight.jpg 962 1920 Travis Reilly https://psychedelicspotlight.com/wp-content/uploads/2023/01/PS_LOGO_PRIMARY_DOT_WHT-1.png Travis Reilly2021-12-24 17:53:262022-06-07 23:17:15Psychedelic Business Spotlight – December 24
Psychedelic Business Spotlight – December 24Business, Stock Reports
This week in psychedelic business news: FDA green lights a new psilocybin study; MindMed commences LSD treatment for ADHD; Sage Institute shuffles leadership.